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Loiasis is a filarial disease with a defined geographical 
distribution; its main vectors, Chrysops silacea and C. 
diddiata, are confined to the great rainforest of Central 
Africa, from Zaire to Nigeria (HAWKING, 1977; FAIN, 
1981). Within some endemic regions it is second only to 
malaria in contributing to the demand for medical con- 
sultation (PINDER, 1988). 
Humans are the only reservoir for Loa loa. Simian Loa 
is a sympatric but divergent species which has a differ- 
ent host-vector-parasite complex (RHODAIN, 1980). At 
present, no efficient method exists for controlling 
CItrysops and the only way to control loiasis is to treat 
the endemic community. At community level, this strat- 
egy is justifiable by the low population density of 
Chysops (c. 1000 flies per km2) and its short flight range 
(usually <5 km) (BEESLEY & CREWE, 1963; CHIPPAUX et 
al., in press). Both characteristics are conducive to a 
marked impact of community-based filaricidal treat- 
ment on the transmission of the parasite (NOIREAU, 
1990). 
Ivermectin mass treatment for onchocerciasis, initi- 
ated in West Africa, has been used in loiasis endemic 
areas in Cameroon since 1991. It brought about a 
marked decrease in microfilarial loads, and the drug was 
safer than diethylcarbamazine (CARME et al., 1991; CHIP- 
PAUX et al., 1992; MARTIN-PRÉVEL et al., 1993). There- 
fore, it seemed feasible to control both filariases with the 
same treatment. This study investigated the effect of re- 
peated ivermectin treatments, over a period of 2 years, 
on the reservoir of L. loa in one village. The aim was to 
assess the feasibility of a large scale loiasis control pro- 
gramme. 
The study took place in Ngat, a village in the tropical 
rain forest of southern Cameroon (3'23'N, 11'34'E), 
where loiasis is hyperendemic (30% microfilaraemia 
rate). The prevalence of Onchocerca volvulus was below 
15%, and Mansonella perstans was the only other filarial 
parasite of importance (16% prevalence). In a previous 
longitudinal study carried out in Ngat during the year 
preceding the first ivermectin distribution, GARCIA et al. 
(1995) demonstrated the stability of the individual's L. 
Zoa microfilarial status. The population under study 
comprised about 700 inhabitants, of whom 450 were per- 
manent residents, mostly field workers of the Ewondo 
tribe; 868 people were enrolled in the 2-year survey, in- 
cluding permanent residents, relatives living in nearby 
villages, and seasonal workers. The mean age was 28.6 
years (range 0-87); the ma1e:female ratio was 0.94. Of 
the 320 subjects who left the study, 12 (3.7%) died, 40 
(12.5%) refused treatment, and 268 (30.9%) left the vil- 
lage. Most of the latter were students who left to attend 
school and young women who left to get married. 
During the second year of treatment, 130 new inhabi- 
tants settled in the village. They therefore became part 
of the parasite reservoir and were included in the study. 
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Fig. 1. Reduction of the median Loa loa microfilarial density in 
patients receiving ivermectin every 3 months; vertical lines in- 
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Fig. 2. Reduction of Loa Zoa prevalence (columns) and micro- 
filarial density (line) in patients receiving ivermectin every 3 
months. 
This did not modify the initial population charac- 
teristics. The parasitological indices were, however, in- 
creased by the arrival of an untreated subpopulation 
with a microfilaraemia prevalence of 16% and a micro- 
filarial density of 1.5 microfilariae/O-l-pL of blood. 
Health education activities were actively maintained 
during the study period, so that only 20 people (2.3%) 
did not receive any ivermectin treatment during the 
course of the study. 
From April 1993 to April 1995, the population was 
treated every 3 months with 0.2 mg/kg of ivermectin. 
The drug was administered to all present available and 
compliant persons who agreed to be treated and for 
whom it was not contraindicated (CHIPPAUX et al., 1992). 
Before the start of microfilaricidal therapy, and after 
the first and second years of treatment, thick blood 
films, prepared with 30 pL of blood and stained with 
Giemsa's strain, were taken from the study population. 
Side effects of the drug were monitored and treated by 
physicians 8 d after the first drug distribution and 5 d af- 
ter subsequent ones. The major problem encountered 
was the occurrence of severe adverse reactions to the 
first treatment among people who had very high micro- 
filaraemia (CHIPPAUX et al., 1993). 
Treatment coverage varied from 46% to 80% in the 
whole population, and from 74% to 94% among people 
with L. Zoa microfilaraemia; the 219 subjects with micro- 
filaraemia were encouraged to participate in treatment 
in order to improve the impact on transmission. Other 
dwellings and important roads were about 10 km distant 
from the village, which diminished the possibility of in- 
teraction between the treated population and untreated 
infected persons and of the introduction of infected 
Clzysops from outside the study area. 
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The effect of treatment on the human parasite reser-. 
voir was dramatic. Thé reduction in the median micro- 
filarial density was almost logarithmic (Fig. 1). After 2 
years of treatment, the Williams’s geometrical mean mi- 
crofilarial density was reduced to 8% of its initial value 
(Fig. 2), and no microfilaria was seen in the thick blood 
films of 80% of people who had been microfilaraemic be- 
fore treatment. The decrease in prevalence of micro- 
filaraemia was particularly significant after the first year 
of treatment, suggesting a cumulative effect of iver- 
mectin on the adults of L. Zoa and/or on the fecundity of 
the female worms. 
A longer survey of the incidence of the disease, par- 
ticularly in children less than 5 years old (who were not 
treated during this study due to ivermectin contraindi- 
cation), and a study of the changes in the concomitant 
entomological transmission indices, would be helpful in 
estimating the effect on transmission of large-scale con- 
trol of the reservoir L. Zoa. 
In conclusion, whereas the impact of microfilaricidal 
treatment on the parasite reservoir has been demon- 
strated in one village in a hyperendemic area, the impact 
on transmission still remains to be assessed. Further 
studies are required to appraise the actual risk of severe 
adverse reactions. Mass treatment with ivermectin in 
loiasis endemic area should, in the interim, be carried 
out with caution (DUCORPS et al., 1995). 
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I First Annual Amazon Travel Medicine Course IO-18January 1997 
This course is designed for health-care professionals who prepare persons for travel or who care for those with 
post-travel illness. It will be taught in English by experts from the USA, Canada and Europe. Participants will 
spend 5 days down-river from Iquitos, Peru, in jungle lodges in the Amazonian rain forest and 2 days in Lima. 
The course director is  Dr David O. Freedman, Director of the University of Alabama at Birmingham Travelers’ 
Health Clinic. 
Further information can be obtained from Charlotte DeFrances at the University of Alabama at Birmingham, 
Alabama, USA; phone t l 2 0 5  428 1700 or 4-1 800 633 4734. 
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